Medicsen Smartpatch: Safety & Performance (SOUNDD)
Condition(s) studied
Investigational drug(s) / intervention(s)
Medicsen Smartpatch: This intervention consists of administering the drug using the Medicsen Smartpatch, a non-invasive, needle-free drug delivery device that utilizes sonophoresis technology to enhance absorption through the skin.
Subcutaneous (SC) single dose: This intervention consists of administering the drug via standard subcutaneous injection using a pre-filled pen injector
Study summary
The goal of this clinical trial is to understand the efficacy of Medicsen's Smartpatch to deliver drugs through the skin in healthy volunteers. The main questions it aims to answer are:
* Is the administration with Medicsen Smartpatch safe for the patient?
* Can Medicsen's Smartpatch be used to effectively administer drugs to patients?
Researchers will compare administration with Medicsen's Smartpatch with the subcutaneous administration of the drug to see if the efficacy and safety are comparable
Participants will be asked to fill a tolerability survey after receiving each of the two interventions: Subcutaneous administration and Medicse's Smartpatch.
Blood samples will be taken at different timepoints to asses for efficacy of each treatment.
Eligibility
Primary outcome measure(s)
- Stage 1 - Device-related adverse events (adverse device effects; ADEs) — Periprocedural
Primary Outcome Measure of Stage 1. Incidence and severity of ADEs is assesed, with special focus on those occurred at the site of administration and those leading to treatment interruption. - Stage 1 - Assessment of local tolerability through questionnaires and visual examination — Periprocedural
Primary Outcome Measure of Stage 1. Subject-reported sensations (pain/burning, itching/stinging, discomfort) during and after administration are assesed through questionnaires. Dermatologist-evaluated skin signs (erythema, edema, vesicles, crusts/exudate, scaling/lichenification, hematomas/bleeding, tenderness) are assesed through visual examination. - Stage 2 - Area under the curve (AUC0-∞ and AUC0-t) — Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose
Primary Outcome Measure of Stage 2 - Stage 2 - Peak plasma concentration (Cmax) — Prior intervention and 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 120, 180, 240 minutes post-dose
Primary Outcome Measure of Stage 2
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospital Universitario Ramon y Cajal | Madrid | Madrid |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07615959 on ClinicalTrials.gov ↗ ← All trials in Spain